Form 4: BIOADAPTIVES Director Receives Convertible Stock Compensation

BIOADAPTIVES, INC. Director Mark P. Frissora received 2,565 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Mark P. Frissora, a Director of BIOADAPTIVES, INC. (BDPT), acquired 2,565 shares of Series D Convertible Preferred Stock.
• The acquisition was compensation for board services, pursuant to a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation.
• The conversion right does not expire, but shares cannot be converted until six months after issuance, except in liquidation.
• Each Series D Convertible Preferred Stock share carries 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation.
• Following this transaction, Mark P. Frissora beneficially owns 59,779 shares of Series D Convertible Preferred Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive due to the alignment of director interests with shareholders through equity compensation, though it represents a routine and expected event.

Positives

• The issuance of Series D Convertible Preferred Stock as compensation aligns the director's financial interests with the long-term performance and shareholder value of BIOADAPTIVES, INC.

Risks

• A 4.9% beneficial ownership limitation restricts the immediate full conversion of Series D Convertible Preferred Stock into common stock.
• Conversion of Series D Convertible Preferred Stock is restricted for six months after the date of issuance, except in the case of liquidation.

Future Outlook

The acquired Series D Convertible Preferred Stock will become convertible into common stock on August 1, 2026, six months after its issuance, subject to a 4.9% beneficial ownership limitation.

Industry Context

StockSavvy.ai notes that the issuance of equity compensation to directors is a common practice across industries, designed to align the interests of management with those of shareholders. This particular filing reflects a routine compensation event for an existing director at BIOADAPTIVES, INC.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity compensation aims to align the director's interests with long-term shareholder value. Potential dilution from future conversions is subject to a beneficial ownership limitation.

Next Steps

• The Series D Convertible Preferred Stock will become eligible for conversion into common stock on August 1, 2026.

Key Dates

Recommendation

This Form 4 reports a routine compensation grant to an existing director and does not contain new fundamental information that would significantly alter the investment thesis for BIOADAPTIVES, INC. It primarily serves to align director interests with shareholders, which is generally a neutral to slightly positive factor.

Keywords

BDPT, BIOADAPTIVES, Form 4, insider transaction, director compensation, convertible preferred stock, Mark P. Frissora, corporate governance